67. Polycystic kidney disease Clinical trials / Disease details


Clinical trials : 216 Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

  
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04680780
(ClinicalTrials.gov)
January 10, 20211/10/2020Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)ADPKDOther: Ketogenic diet;Other: 3-days water-fasting;Other: ControlUniversity of CologneNULLActive, not recruiting18 Years60 YearsAll63N/AGermany
2NCT03102632
(ClinicalTrials.gov)
June 1, 201727/3/2017A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney DiseaseA Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic KidneyOther: High Water IntakeThe Rogosin InstituteWeill Medical College of Cornell UniversityActive, not recruiting18 Years65 YearsAll10N/AUnited States
3NCT02933268
(ClinicalTrials.gov)
September 26, 201618/9/2016High Water Intake in Polycystic Kidney DiseaseDetermining Feasibility of Randomisation to High vs ad Libitum Water Intake in Polycystic Kidney Disease: The DRINK Randomised Feasibility TrialAutosomal Dominant Polycystic Kidney DiseaseDietary Supplement: High water intake;Other: Ad libitum water intakeCambridge University Hospitals NHS Foundation TrustPKD Charity;Addenbrookes Charitable Trust;British Renal Society & British Kidney Patient AssociationCompleted16 YearsN/AAll42N/AUnited Kingdom
4NCT02776241
(ClinicalTrials.gov)
September 20154/5/2016Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney DiseaseEffect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney: The HYDRA StudyADPKDOther: waterRigshospitalet, DenmarkAarhus University HospitalCompleted18 YearsN/AAll40N/ADenmark
5NCT02527863
(ClinicalTrials.gov)
February 201518/2/2015Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemThe Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Central Hemodynamics During Baseline Conditions and After Inhibition of the Nitric Oxide System in Patients With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney DiseaseDrug: Tolvaptan;Drug: PlaceboRegional Hospital HolstebroAarhus University HospitalCompleted18 Years65 YearsAll18Phase 2Denmark
6EUCTR2014-001973-15-DK
(EUCTR)
18/11/201427/06/2014The effcts of tolvaptan on renal handling of water and salt, hormones in the blood at the circulation, during blocking of the nitric oxide (NO) system in patients with autosomal dominant polycystic kidney diseaseRenal Handling of Water and Sodium in Autosomal Dominant Polycystic Kidney Disease.The effects of tolvaptan on renal handling of water and sodium , vasoactive hormones and central hemodynamics during baseline conditions and after inhibition of the nitric oxide system in patients with autosomal dominant polycystic kidney disease - TOPO HyponatreamiaSIADH ( Syndrome of Inappropriate Antidiuretic Hormone Secretion) OverhydrationAutosomal dominant polycystic kidney disease
MedDRA version: 17.0;Level: LLT;Classification code 10021038;Term: Hyponatremia;System Organ Class: 100000004861
MedDRA version: 17.0;Classification code 10040626;Term: SIADH;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07]
Trade Name: Samsca
Product Name: Tolvaptan
Product Code: C03XA01
INN or Proposed INN: Tolvaptan
Other descriptive name: TOLVAPTAN
University Clinic in Nephrology and Hypertension, Department of Medical ResearchNULLNot RecruitingFemale: yes
Male: yes
Denmark
7NCT02225860
(ClinicalTrials.gov)
May 201420/8/2014Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseLow Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKDAutosomal Dominant Polycystic Kidney Disease (ADPKD)Behavioral: Diet and water adjustmentTufts Medical CenterNULLCompleted18 Years60 YearsAll34Phase 2/Phase 3United States
8NCT00784030
(ClinicalTrials.gov)
November 200831/10/2008High Water Intake to Slow Progression of Polycystic Kidney DiseaseThe Effect of Water Loading on Urinary BiomarkersKidney, Polycystic, Autosomal DominantOther: WaterNew York University School of MedicineNULLCompleted18 Years65 YearsAll23N/AUnited States
9NCT00759369
(ClinicalTrials.gov)
September 200824/9/2008Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)Water as Therapy in Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney DiseaseOther: Water prescriptionUniversity of KansasNULLCompleted18 Years50 YearsBoth11N/AUnited States